나노엔텍

039860KOSDAQ의료용 기기 제조업

63.3 / 100

Reference Date: 2026-07-24

Financial Score18.0 / 40

News Sentiment21.3 / 25

Momentum14.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but PER raises overvaluation concerns. Rose 8.0% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

NanoEntek develops, manufactures, and sells in vitro diagnostic medical devices and life science experiment equipment based on the Lab-On-a-Chip (LOC) platform. The company leverages its core Bio-MEMS technology, integrating microfluidics and nanotechnology, to enable applications in cancer diagnostics, cell counting, and other fields. It operates a U.S. sales subsidiary and a B2B healthcare service arm, expanding its global market presence.

Number of Employees

141people

Average Salary

53.2M KRW

Score Calculation Basis

Detailed Financial Score

PER

84.79Industry Average 20.040.0Point

4.2x industry avg (risky)

PBR

1.67Industry Average 1.142.5Point

Higher than industry avg (caution)

ROE

1.92Industry Average 8.001.0Point

Well below industry avg

Debt Ratio

1.76Industry Average 11.658.0Point

Half of industry avg (excellent)

Trend 2023~20256.5 / 10 points

Revenue Growth Rate

2.5 / 3

Avg ▲19.3% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲102.6% (2-year basis)

ROE Trend

1.0 / 4

Avg ROE 0.3% (improving, 3yr)

Detailed News Sentiment

3 totalPositive 3Neutral 0Negative 0Average Sentiment Score 85

Positive
나노엔텍, 조혈줄기세포계수기 美FDA 냉동 HPC-A 검체 추가 승인
나노엔텍의 FDA 승인 확대로 ADAM II 조혈줄기세포계수기의 냉동 HPC-A 검체 적용이 가능해져 시장 경쟁력 강화 기대.
Positive
나노엔텍, 길리어드 자회사 카이트파마에 자동화 세포분석 로봇 공급
나노엔텍의 카이트파마 공급 계약으로 글로벌 CGT 시장 진출 가속화.
Positive
글로벌 신제품의 ‘0번지’… 한국이 테스트베드로 부상한 이유
글로벌 브랜드들이 한국을 신제품 출시의 테스트베드로 선택하는 추세로, 나노엔텍과 관련된 시장 접근성 및 소비자 반응 속도 향상이 긍정적 영향을 미칠 것으로 예상됩니다.

Detailed Momentum

52-week position3.0Point

52w lower range (20%)

Current 3,985Won52-week high 7,67052-week low 3,030

1-month return5.0Point

1m +7.99% (rising)

Volume trend6.0Point

Volume surge

Detailed Disclosure

0 totalPositive 0Neutral 0Negative 0